New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized...

Related Keywords

China ,Puerto Rico ,Australia ,Monash ,South Australia ,Japan ,Melbourne ,Victoria ,Coll Cardiol ,Michael Strapazon ,Trish Rowland ,Stephenj Nicholls ,Davidm Reese ,Exchange Commission ,Amgen ,European Union ,Drug Administration ,Monash University Victorian Heart Institute ,World Health Organization ,Beigene Ltd ,Cardiovascular Therapeutic ,Primary Hyperlipidemia ,Cardiovascular Outcomes Trial ,Pharmaceutical Precautions ,Adaptive Biotechnologies ,Thousand Oaks ,Amgen Data ,Coronary Artery Disease ,Analysis From ,World Health ,Accessed July ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Roadcast Feed Annoucement ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,